Amylyx Pharmaceuticals

The work to support the global #neurodegenerative disease community never stops. Subscribe for the latest updates from Amylyx at www.amylyx.com.

We’re looking forward to attending the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease and presenting the design of our Phase 3 LUCIDITY clinical trial for the treatment of post-bariatric hypoglycemia (#PBH). More details below. #WCIRDC24

#TeamAmylyx is excited to be in Montreal this weekend at Motor Neurone Disease (MND) Association’s 35th Annual Symposium on ALS/MND (#alsmndsymp). More details on the poster we’re presenting below. 

#Wolframsyndrome is a rare, monogenic neurodegenerative disease with no disease-modifying treatment options for the ~3,000 people in the U.S., and more around the world, who are living with this condition. Learn more about the mechanism of disease informing our scientific approach below.

Today, we announced the design of our Phase 3 LUCIDITY clinical trial for our investigational, first-in-class GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia. We plan to initiate LUCIDITY in the first quarter of 2025. Learn more about LUCIDITY and the previous clinical trial data that informed our Phase 3 trial: https://bit.ly/41nOapX

Our work, our motivation, and the core values that guide us are deeply interwoven. Learn more about each of the core values guiding #TeamAmylyx below.

Symptomatic post-bariatric hypoglycemia (#PBH) affects ~8% of people who have undergone bariatric surgery and occurs, on average, 1-3 years post-surgery. PBH is thought to be caused by an excessive glucagon-like peptide-1 (GLP-1) response leading to hypoglycemia and impaired quality of life. Learn more about PBH below.

Our work at Amylyx means we often confront the difficult truths of diseases with high unmet needs, including those of children living in families with ALS. We recently watched LUKi & the Lights (linked below) together as a team and found it a compassionate and honest depiction of ALS.    Our heartfelt thanks to Melinda Kavanaugh, PhD, LCSW, President of Global Neuro YCare and recent Amylyx Beyond the Diagnosis guest speaker, for sharing this animated film with us and empowering us to further raise awareness. Watch LUKi and the Lights here: https://lnkd.in/ed-uMxzq

We’re excited to return to the ALS ONE Research Symposium, joining others in industry to discuss current research that’s underway around the world. More details on Amylyx’ presentation below.

We’re looking forward to attending the Child Neurology Society (CNS) Annual Meeting next week in San Diego, where we’ll be sharing results from our HELIOS trial in #Wolframsyndrome. More details below. #CNSAM